



































dJournal of Chromatography B, 877 (2009) 1516–1522
Contents lists available at ScienceDirect
Journal of Chromatography B
journa l homepage: www.e lsev ier .com/ locate /chromb
uriﬁcation of polyclonal anti-conformational antibodies for use in afﬁnity
election from random peptide phage display libraries: A study using
he hydatid vaccine EG95
.J. Read ∗, C.G. Gauci, M.W. Lightowlers
he University of Melbourne, Veterinary Clinical Centre, 250 Princes Highway, Werribee, Victoria 3030, Australia
r t i c l e i n f o
rticle history:
eceived 7 October 2008
ccepted 23 March 2009
vailable online 28 March 2009
eywords:
a b s t r a c t
The use of polyclonal antibodies to screen random peptide phage display libraries often results in the
recognition of a large number of peptides thatmimic linear epitopes on various proteins. There appears to
be a bias in the use of this technology toward the selection of peptides thatmimic linear epitopes. Inmany
circumstances the correct folding of a protein immunogen is required for conferring protection. The use
of random peptide phage display libraries to identify peptidemimics of conformational epitopes in thesehage display
onospeciﬁc antibodies
chinococcus granulosus
cases requires a strategy for overcoming this bias. Conformational epitopes on the hydatid vaccine EG95
have been shown to result in protective immunity in sheep, whereas linear epitopes are not protective. In
this paper we describe a strategy that results in the puriﬁcation of polyclonal antibodies directed against
conformational epitopes while eliminating antibodies directed against linear epitopes. These afﬁnity
puriﬁed antibodies were then used to select a peptide from a random peptide phage display library




Hydatid disease is a zoonotic parasitic disease with a pan-
lobal distribution. It results in considerable human morbidity and
ortality, particularly in developing countries. The disease also
ccurs in economically important mammals such as sheep and
attle. Hydatid disease is caused by the metacestode stage of the
anine tapeworm Echinococcus granulosus. A recombinant vaccine
nown as EG95 has been developed that can be used to prevent
ydatid infection in animal intermediate hosts [1,2]. The EG95 vac-
ine comprises a single recombinant antigen and much progress
as been made with its characterisation. It induces complement-
xing antibodies that kill the invading oncosphere early in an
nfection. Woollard et al. [3] discovered four linear epitopes on
G95 using overlapping synthetic peptides. However, these epi-
opes were found to be of a minor speciﬁcity in the total immune
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response and when they were used as an immunogen, they were
not able to elicit protective antibodies [4]. Woollard et al. [5] also
produced three overlapping polypeptides that span the length of
EG95. These polypeptides contained all the previously discovered
linear epitopes, but each lacked the tertiary structure of EG95.
These polypeptides failed to protect sheep from hydatid disease
when used as an immunogen. A schematic representation of these
polypeptides, and their relationship to the identiﬁed linear epitopes
and full length EG95 is shown in Fig. 1. Since linear epitopes do not
protect against infection, it remains that the protective epitopes of
EG95are conformational innature and the entire lengthof theEG95
molecule is required to produce immunity [5]. The current study
is aimed towards identiﬁcation of peptides that have the poten-
tial to immunologically mimic one or more of these conformation
epitopes.
Random peptide phage display (RPPD) libraries contain large
numbers of phages that display different peptides of randomamino
acid sequence. These random peptides are capable of binding to
a wide variety of ligands in a process known as afﬁnity selec-
tion. When these libraries are used to identify peptides that mimic
antigen epitopes, the most common ligand used is antibody. The
Open access under CC BY license.majority of published papers describing the use of antibody as
the basis for afﬁnity selection have used monoclonal antibodies.
Monoclonal antibodies have certain desirable properties which
make them the usual choice in epitope/mimotope selection experi-
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omogeneity that results in the ability to treat the antibody as a
eﬁned chemical, and their precise speciﬁcity that identiﬁes a sin-
le epitope. The homogeneity and precise speciﬁcity ofmonoclonal
ntibodies mean that peptides selected using phage display can be
ssessed for afﬁnity to the antibodies and the results are not con-
ounded by the inclusion of peptides that mimic more than one
pitope. Monoclonal antibodies have been used to clearly identify
eptides that mimic both linear and conformational epitopes [6,7].
However, there are also limitations in using monoclonal anti-
odies. First, monoclonal antibodies are more labour intensive and
xpensive toproducewhen compared topolyclonal antibodies. Fur-
hermore, amonoclonal antibody can only be a useful target if there
s evidence that it recognises an epitope that has a protective func-
ion in vivo. Epitopes recognised bymonoclonal antibodiesmay not
e protective because some may be of minor speciﬁcities, while
thers may not be accessible to the immune system because of
lycosylation or other conformational factors [8]. Polyclonal anti-
odies, on the other hand, target multiple epitopes and so contain
peciﬁcities that cover the full range of epitopes on an antigen that
re presented to the immune system. Polyclonal antibodies typi-
ally havehigher avidity for the antigen inquestion [9] andaremore
olerant of minor changes in the antigen thanmonoclonal antibod-
es, for example differences in glycosylation, or mild denaturation
10].
Preliminary experiments using afﬁnity selection of randompep-
idesonpolyclonal antibodies fromsheep thathavebeenpreviously
accinatedwith EG95were performed [11]. Interestingly, this afﬁn-
ty selection resulted in a large number of clones exhibiting a
eptide insert sequence with a strong consensus motif that cor-
esponded to one of the linear epitopes of EG95 discovered by
oollard et al. [3]. This linear epitope was shown to be of minor
peciﬁcity and not to be protective.
This result highlights a bias that appears tobe inherent in theuse
f polyclonal antibodies as the target for RPPD. Craig et al. [12] ﬁrst
lluded to this bias. They used 15 different RPPD libraries to pan
olyclonal antibodies to either hen eggwhite lysozyme or worm
yohemerythrin and found that all 102 peptides that they selected
ould be aligned to linear epitopes on either protein. This is despite
he majority of antibodies present in a polyclonal sample being
irected against conformational epitopes [13,14].
Thenumber of studies that usepolyclonal antibodies as thebasis
or afﬁnity selection of random peptides is relatively few. Only two
tudies [15,16] found peptides thatmimic only conformational epi-
opes. With the exception of Iniguez et al., [17], all other studies
where the amino acid sequence of the target was known) found
hat the majority of selected peptides could be aligned to linear
pitopes [12,15,16,18–38]. Hence when RPPD technology is applied
o polyclonal antibodies, it is likely that there is an inherent bias
oward the selection of peptides thatmimic linear epitopes. If RPPD
ibraries are to beused for thediscovery of peptides thatmimic con-
ormational epitopes using polyclonal antibodies, then a method
ust be devised to eliminate this bias.
The intent of this study is to present amethod for afﬁnity puriﬁ-
ation of polyclonal antibodies against EG95 that are depleted of
inear epitope speciﬁcities. These anti-conformational antibodies
re then used to discover peptides that can mimic the conforma-
ig. 1. Schematic representation of full length recombinant EG95 and three overlapping t
re shaded.B 877 (2009) 1516–1522 1517
tional epitopes of EG95. Further details on the evaluation of these
peptides can be found elsewhere [39].
2. Materials and methods
2.1. Production of GST and GST fusion proteins in Escherichia coli
Eight recombinant proteins were used for immunisation, afﬁn-
ity puriﬁcation and ELISAs. The derivation of vectors and the
expression of these proteins have been detailed elsewhere [1,3,40].
Brieﬂy, glutathioneS-transferase (GST) and fusionproteins contain-
ing three, non-protecting, truncated and overlapping derivatives
of EG95 were expressed from the pGEX-3-EX expression plas-
mid (Amersham Pharmacia Biotech, Sweden) in E. coli JM109
strain (New England Biolabs, USA). The full length recombinant
EG95 was also expressed from the pGEX-3-EX expression plas-
mid and from the pMAL-C2 (New England BioLabs, USA) plasmid
as a maltose binding protein (MBP) fusion in E. coli BB4 cells
(Stratagene, USA). GST and GST fusion proteins were puriﬁed from
isopropyl-1-thio--galactoside (IPTG) induced bacterial cell cul-
tures by glutathione-agarose afﬁnity chromatography as described
by Smith and Johnson [41]. MBP fusion proteins were afﬁnity puri-
ﬁed on amylose resin (New England BioLab, USA) according to
themanufacturer’s recommendations. The three truncatedproteins
were designated EG954–74, EG9554–109, and EG9592–156, subscripts
referring to the location of the amino acid residues in the trans-
lated native protein. A graphical representation of these proteins is
shown in Fig. 1.
2.2. Immunisation of experimental animals
Two 3-year-oldMerinowethers were used for the production of
anti-EG95–GST antibodies. Immunisation occurred on three occa-
sions with 100g of EG95–GST and 1mg of Quil-A (adjuvant) in
2mlofphosphatebuffered saline (145mMNaCl, 2.7mMKCl, 12mM
Na2HPO4, 1.2mM KH2PO4, pH 7.4) (PBS). The second immunisa-
tion took place 14 days after the initial immunisation, and the third
immunisation 45 days after the initial immunisation. Serum was
collected at day 59.
2.3. Preparation of afﬁnity puriﬁcation columns
A total of six protein afﬁnity puriﬁcation columns were pro-
duced. GST, EG954–74–GST, EG9554–109–GST, EG9592–156–GST, E. coli
lysate andEG95–GSTwere ligated to agarosebeads viaCNBr linkage
(CNBr-Sepharose, Amersham, Sweden). The fusion proteins were
prepared for the linking reaction by membrane ﬁltration (0.2m
pore size) (Minisart CE; Sartorius, Germany) and concentration
using a 10kDa concentrator (Vivaspin20, Sartorius, Germany). The
buffer was exchanged to a coupling buffer (0.2M NaHCO3, 0.5M
NaCl, 2M urea, pH 8.3) using Vivaspin 20 Diaﬁltration Cups (Sarto-to manufacturer’s guidelines. Brieﬂy, 1 g of dried CNBr-Sepharose
powder was allowed to swell in ice cold 1mM HCl for 15min. The
beads were washed in 50ml of ice cold 1mM HCl. A ﬁnal wash in
coupling buffer was performed.
runcated versions of EG95. Linear epitope regions identiﬁed by Woollard et al., [3]






















































Fig. 2. Schematic illustrating afﬁnity puriﬁcation technique. Clariﬁed pooled antis-
erawas diluted in binding buffer. The diluted serumwas applied to theﬁvedepletion
columns – GST, EG954–74, EG9554–109, EG9592–156 and E. coli lysate. The ﬂow through
was reapplied to the depletion columns three times. Washed columns were eluted
of antibodies. Anti-GST antibodies were collected. The ﬂow through from the ﬁve518 A.J. Read et al. / J. Chrom
Concentrated protein and activated CNBr-Sepharose beadswere
ixed for 2h at room temperature. The unbound protein was
ashed with two washes of coupling buffer. Remaining activated
ites were blocked with three column volumes of glycine buffer
0.2M glycine, pH 8.0) at 4 ◦C overnight. Alternating washes with
oupling buffer followed by acetate buffered saline (0.1M acetate,
.5M NaCl, pH 4.0) were performed four times in order to remove
esidual glycine and regenerate the column. Finally each column
as equilibrated with three washes of PBS.
.4. Afﬁnity puriﬁcation of anti-EG95 and anti-GST antibodies
.4.1. Depletion of unwanted antibody speciﬁcities
Antisera from the immunised sheep were pooled, clariﬁed
nd diluted with an equal volume of binding buffer (0.01M
odiumphosphate, 0.15MNaCl, 0.01MEDTA pH7.0). Antiserawere
assed three times serially through the GST, EG954–74, EG9554–109,
G9592–156 and E. coli lysate columns (Fig. 2). Columns were then
ashed with 10 column volumes of binding buffer. The wash
olution and depleted antisera was concentrated using a 100kDa
oncentrator (Vivaspin100, Sartorius, Germany) back to the origi-
al volume. The depleted serum was then passed three times over
he EG95–GST column in order to capture anti-EG95 antibodies.
.4.2. Elution of afﬁnity puriﬁed antibodies
The EG95–GST and GST columns were equilibrated with 10 col-
mn volumes of PBS. Antibodies were eluted in 1ml fractions with
low pH buffer (0.1M glycine/HCl, 0.15M NaCl pH 2.6). Fractions
ere neutralised with 1M Tris, pH 9.0. Individual fractions with
ptical density at 280nm of greater than 0.2 were pooled and the
otal volume of this pool was concentrated using a 100kDa con-
entrator (Vivaspin100, Sartorius, Germany) back to the original
olume. The puriﬁed antibodies against conformational epitopes
f EG95 are referred to as anti-cEG95, while the antibodies eluted
rom the GST column are referred to as anti-GST.
.5. Enzyme linked immunosorbent assays (ELISA)
Determination of antibody titres was performed after Woollard
t al. [3]. Microtitre plates (Greiner, USA) were coated with 50l
f a 0.5g/ml solution of EG95–MBP in carbonate buffer (50mM
arbonate, pH 9.0) overnight at 4 ◦C. Wells were blocked for 1h at
oom temperature with 100L of 5% skim milk in PBS (SMPBS).
est samples were incubated at room temperature for 1h. Donkey
nti-sheep horseradish peroxidise (Sigma, USA)) diluted 1:2000
n SMPBS was added for 1h at room temperature. TMB substrate
0.09M sodium acetate, 0.01M citric acid, 0.417M 3,3′,5,5′-tetra-
ethylbenzidine,H2O2 (0.00036%, v/v))was left to develop at room
emperature for 30min. The reaction was stopped by the addition
f 0.5M H2SO4. Absorbance values were read at 450nm using an
psys MRTM absorbance reader (Dynex Technologies, USA). The
itre was deﬁned as the reciprocal of the dilution that gave an
bsorbance reading of 1.0. Anti-GST antibody titres were deter-
ined in a similar manner except that a 1g/ml solution of GST
as used to coat themicrotitre plates. All titrationswere performed
n duplicate and results shown as mean.
.6. Immunoblot assays
Nitrocellulose 0.2m (HybondTM ECLTM, GE Healthcare, USA)
as pre-wetted in Towbin transfer buffer (25mM Tris, 193mM
lycine, 20% methanol, pH 8.4). For Western assays, 1g of recom-
inantproteinswas transferred fromSDS-PAGE. Fordot-blot assays,
g of recombinant proteins EG95–GST, GST and EG95–MBP was
potted on to the nitrocellulose membrane. The membrane wasdepletion columnswas applied to an EG95–GST column. The ﬂow through from this
column was reapplied three times. Washed EG95–GST column was eluted of anti-
bodies and the antibodies against conformational epitopes on EG95 were collected
(anti-cEG95).
subsequently dried and incubated for 1h in SMPBST to block non-
speciﬁc binding sites. Incubation with primary antibodies took
place for 1h at room temperature. Whole serum pools from sheep
prior to, and after immunisation with EG95–GST, were diluted
1:2000 in SMPBST. Afﬁnity puriﬁed anti-cEG95, anti-GST, anti-E100
and anti-G1 were diluted to 1g/ml. The primary antibodies were
incubated for 1h at room temperature with a 1:2000 dilution of
polyclonal donkey anti-sheep IgG-HRP (Sigma, USA) conjugate in
SMPBST. The antibodies on the paper were detected and visualised
by Enhanced Chemiluminescence (ECL; Amersham Biosciences).
2.7. Afﬁnity selection with random peptide phage display librariesTwo different phage display libraries were used, each express-
ing an unconstrained random peptide at the N-terminus of the pIII
capsid protein. The PhD-12 phage Display Kit (New England Bio-
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pproximately 1×109 unique random peptide inserts. The second
ibrary was a 20 mer library that expresses a 20 mer peptide with
pproximately 5×108 inserts (supplied by AdAlta Pty Ltd., Aus-
ralia).
Both the 12 mer and 20 mer libraries were subjected to four
ounds of biopanning using anti-cEG95 antibodies as described by
ead et al. [39]. The 20-mer librarywas biopanned in a similarman-
er using anti-GST antibodies in an attempt to discover aGSTmimic
hat might be used as a control in further experiments.
.8. Clone selection and DNA sequencing
Phages from the ﬁnal round of panning were selected for
equencing. The DNA encoding the PIII random peptide insert was
mpliﬁed by PCR using the following primers:
fd5’2 forward primer 5′-GTATTCTTTCGCCTCTTTC-3′
gIII 3’ reverse primer 5′-TGTAGGCATTCCACAGACAG-3′
Big DyeTM (Applied Biosystems, USA) termination sequencing
as performed on the PCR products. Electrophoresis of the exten-
ion product was carried out at Micromon DNA Sequencing Facility
Monash University, Australia) using an Applied Biosystems model
730 Sequencer.
.9. Peptide synthesis
Peptides corresponding to the sequences of 13 of the phage
lones selected by panning on anti-cEG95 antibodies, along with
hree of the phage clones selected by panning on anti-GST antibod-
es andone irrelevant peptide (R1)were synthesisedusing standard
-ﬂuorenylmethoxycarbonyl (FMOC) chemistry. Synthesiswas per-
ormed manually and using an automated solid phase synthesiser
SymphonyTM automatedpeptide synthesiszer, Rainin-PTIWoburn,
SA) on a cleavable resin. Peptides were puriﬁed by reverse phase
hromatography using Vydac C18 column (100mm×300mm).
The ability of peptides bound to polyethylene glycol polyamide
opolymer (PEGA) or mircotitre plates to react with antisera from
heep immunised with EG95–GST was assessed in a series of pilot
tudies (data not shown).
.10. Afﬁnity puriﬁcation of monospeciﬁc antibodies
The result of the pilot studies indicated that peptide E100, HYK-
LNDPLAAW,waspotentially amimotope forEG95andsuitable for
se as an afﬁnity ligand. Peptide G1, FSLYRVSGFDDPILFAMGPK,was
hosen as an afﬁnity ligand for antibodies directed against GST. NHS
epharose 4 Fast Flow was obtained from Amersham Bioscience.
100 and G1 peptides were coupled to NHS-activated Sepharose
B according to the manufacturer’s instructions. Brieﬂy, peptides
ere coupled at a concentration of 1.0mg/ml for 3h. Unbound
ites were then blocked with Tris–HCl, pH 8.0 buffer. The peptide-
fﬁnity columnswerewashed successivelywith 0.1MNaHCO3, 1M
a2CO3, deionized water, 0.3M glycine–HCl, pH 2.2, and PBS prior
o use.
Pooled serum from sheep immunised with EG95–GST was
iluted in an equal volume of binding buffer (0.01M Na2HPO4,
.15M NaCl, 0.01M EDTA, pH 7.0). The antisera solution was
pplied to the afﬁnity columns four times. Unbound materials
ere removed by washing with six column volumes of binding
uffer. The bound antibodieswere elutedwith low pH buffer (0.1M
lycine/HCl, 0.15M NaCl pH 2.6). Fractions were neutralised with
M Tris, pH 9.0. The fractions with antibody ELISA absorbance val-
es >0.75 were pooled. This pool was concentrated using a 100kDa
oncentrator (Vivaspin100, Sartorius, Germany) back to the originalB 877 (2009) 1516–1522 1519
volume. SDS-PAGEwas used to conﬁrm that only immunoglobulins
had been puriﬁed and the antibody concentration was determined
using theBioradProteinAssay (Bio-Rad,USA). Theantibodieseluted
from the peptide E100 column are referred to as anti-E100, while
the antibodies eluted from the peptide G1column are referred to as
anti-G1.
2.11. Inhibition ELISA
The ability of peptides E100 andR1 to inhibit the binding of anti-
E100 antibody to EG95–MBP was performed in a manner similar
to the ELISA protocol described above. Peptide of varying concen-
trations was premixed with anti-E100 antibody for 1h prior to
addition of the antibody to the EG95–MBP coated wells. Results
were expressed as absorbance at 450nm.
3. Results
3.1. Antibody puriﬁcation
Antisera from sheep immunisedwith EG95–GSTwere collected,
clariﬁed and pooled. The pooled antisera were shown to have a
high titre against EG95–MBP. Afﬁnity puriﬁcation of the antisera
involved the removal of antibody speciﬁcities to the fusion pro-
tein GST, as well as linear epitopes of GST and E. coli proteins. The
removal of these speciﬁcities was attempted using protein spe-
ciﬁc columns. The antisera depleted of these speciﬁcitieswere then
passed through an afﬁnity column containing EG95–MBP. Puri-
ﬁed antibodies were collected from this column. These antibodies
directed against conformational epitopes on EG95were designated
the term anti-cEG95. A schematic representation of the afﬁnity
puriﬁcation is shown in Fig. 2.
Coomassie stained SDS-PAGE showed that the afﬁnity puriﬁed
product was entirely made up of approximately 150kDa proteins
that, when reduced and alkylated, gave two products of approxi-
mately 25 and 50kDa, respectively (data not shown).
ELISA studies showed that the anti-cEG95 antibody solutionwas
highly speciﬁc for EG95 (Fig. 3A). Likewise the anti-GST antibody
solution was speciﬁc for GST (Fig. 3B). Speciﬁcity analysis revealed
that the ratio of EG95–MBP titre to GST titre was over 2000 times
greater in the anti-cEG95 antibody solution compared to the orig-
inal pooled antisera. The ratio of GST titre to EG95–MBP titre in
the anti-GST antibody solution was over 1000 times greater com-
pared to the original pooled antisera. The titres of the pooledwhole
antisera and the pooled antisera following depletion of speciﬁc
antibodies is shown in Fig. 3C and D, respectively.
3.2. Antibody speciﬁcity conﬁrmation by dot-blot assay
Dot-blot analysis (Fig. 4) conﬁrmed the speciﬁc separation
of the two antibody pools. Anti-cEG95 antibody recognised
EG95–GST and EG95–MBP, but not GST. Anti-GST antibody recog-
nised EG95–GST and GST, but only weakly recognised EG95–MBP.
3.3. Conformational and linear epitope recognition by Western
blotting
EG95–MBP, EG954-74, EG9554-109, and EG9592-156 were used
to test recognition of conformational as well as linear epitopes
of EG95. Pooled sera from sheep vaccinated with EG95–GST
were shown by Western blot to recognise the entire molecule of
EG95–MBP, as well as the truncated versions containing linear epi-
topes (Fig. 5). Anti-cEG95 antibodies reacted only with the entire
EG95 molecule, but not with the truncated versions of EG95.
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Fig. 3. Comparison of the anti-EG95 and anti-GST titres of afﬁnity puriﬁed antibodies. Th
solutions (anti-cEG95 and anti-GST). Panel A shows IgG afﬁnity puriﬁed to conformational
Panel C shows pooled whole antisera from sheep following third immunisation with EG9
and GST determinants (ﬂow-through fraction – see Fig. 2).
Fig. 4. Dot-blot of recombinant protein antigens reacted with antibody pools from
sheep immunised with EG95–GST. 1g of each protein was spotted onto the nitro-













aane B is the pre-immune pool. Lane C is reactedwith IgG afﬁnity-puriﬁed to confor-
ational epitope/s of EG95 (anti-cEG95). LaneD is reactedwith IgG afﬁnity-puriﬁed
o GST (anti-GST). Lane E is reacted with antibody afﬁnity-puriﬁed to E100 peptide
anti-E100). Lane F is reactedwith antibody afﬁnity-puriﬁed toG1peptide (anti-G1).
.4. Selection of mimotopes for conformational epitopes of EG95
nd GSTTwelve phage clones from the 20mer library, and eight from the
2mer librarywere selected from theﬁnal roundof biopanning and
hown by DNA sequencing to present different peptides. The only
equence homology to EG95 was found in peptide E14, which had
ve amino acid residues at its N terminal that alignedwith residues
ig. 5. Western Blot. Recombinant proteins EG95–MBP (lane 1), EG954–74 (lane 2), EG9554–
rom sheep vaccinated with EG95–GST (Panel A), polyclonal antibodies afﬁnity puriﬁed to
fﬁnity puriﬁed to peptide E100 (Panel C). A Coomasie stained SDS-PAGE displaying recome EG95 (black bars) and GST (grey bars) reactivity of two afﬁnity puriﬁed antibody
epitopes of EG95 (Anti-cEG95). Panel B shows IgG afﬁnity puriﬁed toGST (Anti-GST).
5–GST (day 59). Panel D shows pooled whole antisera following removal of EG95
at positions 115–122 of EG95. It is probable that this peptidemimics
a linear epitope of EG95. The remainder of the peptide sequences
bore no homology to the sequence of EG95 [39].
Eleven remaining selected phage clones were inhibited from
binding to anti-cEG95 antibodies by the presence of EG95–MBP
(data not shown). These 11 peptides were therefore considered
mimics of conformational epitopes on EG95. One of these pep-
tides, E100, was themimotope chosen to be used in further afﬁnity
puriﬁcation studies.
Three unique phage clones were selected from the biopanning
of anti-GST antibodies. One peptide, G1, was the GST mimotope
that was chosen to act as a control peptide in subsequent afﬁnity
puriﬁcation studies.
3.5. Mimotope afﬁnity puriﬁcation
Antibodies were afﬁnity puriﬁed from the sera of sheep vacci-
nated with EG95–GST using columns constructed using the EG95
mimotope (E100) as well as the GST mimotope (G1). A protein dot-
blot assay was used to determine the speciﬁcity of the antibodies
afﬁnity puriﬁed from these columns. The results (Fig. 4) showed
that antibodies afﬁnity puriﬁed to E100 peptide were reactive to
EG95–GST and EG95–MBP, but not to GST. By contrast antibod-
ies afﬁnity puriﬁed to G1 were reactive to EG95–GST and GST.
Western blot showed that the anti-E100 antibodies did react with
EG95–MBP, but did not react with the truncated versions of EG95
109 (lane 3), and EG9592-156 (lane 4) probedwith three antibody sources. Pooled sera
conformational epitopes of EG95 (anti-cEG95) (Panel B) and polyclonal antibodies
binant proteins.









































[ig. 6. Inhibition of anti-E100 antibody binding to EG95 using E100 peptide. The
oncentration of anti-E100 antibody in each well was kept constant at 35ng/ml and
he concentration of free peptides E100 and R1 varied.
Fig. 5). To determinewhether or not the afﬁnity puriﬁed anti-E100
ntibodies represented a monospeciﬁc population the antibodies
ere subjected to an inhibition ELISA using peptide E100 and an
rrelevantpeptideR1.Anti-E100antibodieswere shown tobe inhib-
ted from binding to EG95–MBP by the addition of free peptide
100 in a concentration dependant manner (Fig. 6). The irrelevant
eptide R1wasnot able to inhibit the binding of E100 to EG95–MBP.
. Discussion
In this study, we have reported the puriﬁcation of polyclonal
ntibodies against the conformational determinants of the EG95
ydatid vaccine. Although there have been many reports of the
uriﬁcation of antibodies against a single epitope (monospeciﬁc
uriﬁcation), this appears to be the ﬁrst report of puriﬁcation of
olyclonal antibodies speciﬁcally to conformational epitopes on a
rotein, at the exclusion of linear epitopes. These antibodies have
hen been used to successfully discover peptides that mimic these
onformational epitopes.
Various methods have been advocated for the removal of anti-
odies with unwanted speciﬁcities in polyclonal samples that have
een raised against recombinant antigens. One commonly used
ethod is to add E. coli proteins to the serum solution [42] or to
dsorb non-speciﬁc antibodies on nitrocellulose-bound antigens
43] to remove antibody speciﬁcities derived from exposure to
acterial proteins. Other negative or subtraction immunoafﬁnity
ethods have been described [44,45]. To date no method has been
escribed to purify conformational epitopes frompolyclonal serum
t the exclusion of the linear speciﬁcities.
A two-stage afﬁnity puriﬁcation process was devised to col-
ect polyclonal antibodies against conformational determinants on
G95. The ﬁrst step involved the depletion of unwanted antibody
peciﬁcities, and the second step was the afﬁnity puriﬁcation of
ntibodies against the protective epitopes.
This study used sepharose bound proteins for the depletion
tage of the puriﬁcation process. This involved the production of
fﬁnity puriﬁcation columndisplayingGST and afﬁnity puriﬁcation
olumns displaying truncated versions of EG95. The GST afﬁn-
ty puriﬁcation column was chosen because afﬁnity depletion of
ntibodies speciﬁc to a fusion partner protein has been shown
o be successful in eliminating antibodies with speciﬁcity to the
usion partner [46]. The columns that display the truncated ver-
[
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sions of EG95were used to afﬁnity-deplete linear epitopes of EG95.
These proteins do not contain the conformational epitopes of EG95
molecule [5]. Besides displaying linear epitopes of EG95, these pro-
teins also contain the GST protein. When used as a fusion partner,
GSThasbeenassumed todisplay someepitopes that arenot present
when it is used without a fusion partner [47]. Thus the GST portion
of these columnsdisplaying truncatedEG95wasexpected to adsorb
any antibodies with these speciﬁcities.
Theafﬁnitypuriﬁedanti-cEG95antibodieswere found tobespe-
ciﬁc for EG95. In immuno-dot assays, the antibody reacted with
EG95–MBP, EG95–GST, but not GST (Fig. 4). The anti-GST antibody
speciﬁcities had been effectively removed from the sample. In addi-
tion the antibody solution did not reactwith the truncated proteins
byWestern blot (Fig. 5) indicating that the antibodies were speciﬁc
for conformational epitopes. Additionally, the afﬁnity puriﬁed anti-
EG95 antibodies have been shown to bind to native oncosphere
EG95 and to function in complement mediated oncosphere killing
[39].
The production of polyclonal antibodies against conformational
epitopes on particular antigens is especially applicable for use in
afﬁnity selection using RPPD libraries. Moreover, these antibodies
may be useful agents in applications such as immunoblotting and
immunocytochemistry. We have demonstrated that production of
these antibodies is possible and shown that they are suitable for
use with RPPD libraries. The puriﬁed antibodies are highly spe-
ciﬁc to the antigen of interest, with little cross reactivity to the
fusion partner or linear epitopes on the antigen. The antibodies
directed against linear determinants appear to have been reduced
to such an extent that when used with RPPD libraries none of
the selected peptides bore resemblance to the linear epitopes that
dominatedprevious afﬁnity selection experiments [11]. Further,we
have shown that one of the selected peptide mimotopes is capable
of afﬁnity purifying monospeciﬁc antibodies that bind EG95 con-
formational epitopes. The techniqueof removing antibodies against
linear epitopes described in this paperwould be expected to be able
to generate a target suitable for usewith randompeptide phage dis-
play libraries for any protein antigen where correct folding of the
protein antigen is required for conferring immunity.
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